Dataset from A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.

This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients